An Open-Label, Randomized, Pharmacokinetic Study of vinCRIStine Sulfate LIPOSOME Injection Ready-to-Use (VSLI-RTU) Formulation (1-Vial) and Marqibo® Formulation (3-Vials) in Patients With Hematological Malignancies
Latest Information Update: 07 Oct 2022
At a glance
- Drugs Vincristine (Primary) ; Cyclophosphamide; Doxorubicin; Prednisone; Rituximab
- Indications Haematological malignancies
- Focus Pharmacokinetics
- Sponsors Acrotech Biopharma
Most Recent Events
- 15 Apr 2020 Planned initiation date changed from 15 Mar 2020 to 15 Aug 2020.
- 04 Feb 2020 New trial record